Japan Medical Dynamic Marketing, Inc. · TSE:7600

Japan Medical Dynamic Marketing — H1 FY2026 Earnings Presentation

33 slides from Japan Medical Dynamic Marketing's earnings presentation, Nov 12, 2025

  1. Slide 1: Financial Results Briefing for the Six Months Ended, FY Ending March 2026

    Japan Medical Dynamic Marketing,INC. The Six Months Ended of Financial Results Briefing for the Fiscal Year Ending March 2026 November 12, 2025 Representative Director and President Toshiyuki Hironaka TSE Prime Market Securities code：7600 Copyright © Japan Medical Dynamic Marketing, INC. All Rights

  2. Slide 2: Agenda

    - Agenda - Results for the Six Months Ended Review of the Six Months Ended for 1 ． P. 3 ２ . P.18 of FYE March 2025 the FYE March 2026 - Consolidated net sales P. 4 Key Initiatives and Results of the Six - Months Ended of the FYE March 2026 P.19 - Consolidated Statement of Income P. 5 - SAICO Project

  3. Slide 3: Results for the Six Months Ended of the FYE March 2026

    Results for the Six Months Ended of the FYE March 2026 1 3

  4. Slide 4: Consolidated Net Sales

    Results for the Six Months Ended of the FYE March 2026 Consolidated Net Sales Sales 11,610M yen YoY Change （vs24/9△1.8%） （Unit : Millions of yen） 14,000 11,610M yen （△207M yen） 12,000 10,000 Japanese Market 【After sales deductions】 8,000 6,362M yen （vs24/9 ＋0.3％） 6,000 4,000 U.S. Market 【After conve

  5. Slide 5: Consolidated Statement of Income

    Results for the Six Months Ended of the FYE March 2026 Consolidated Statement of Income FYE Mar.2026 FYE Mar.2025 YoY change interim period interim period （Unit : Millions of yen , ％） Ratio to Amount of Ratio of Ratio to Results change change Results sales sales Net sales 11,610 100.0 △ 207 △ 1.8 11

  6. Slide 6: Comparative YoY Analysis of Operating Income

    Results for the Six Months Ended of the FYE March 2026 Comparative YoY Analysis of Operating income Operating Operating profit decreased by 460 M yen year-on-year, primarily due to a decline in gross Profit profit (down 430 M yen) resulting from reduced sales and increased manufacturing overhead cos

  7. Slide 7: Operating Profit Comparison vs. Initial Forecast for 1H

    Results for the Six Months Ended of the FYE March 2026 Operating Profit Comparison vs. Initial Forecast for 1H Operating Operating profit decreased by 400 M yen compared to the initial plan, despite efforts to Profit control SG＆A (500 M yen). This was due to a decline in gross profit (down 870 M yen

  8. Slide 8: Consolidated Net Sales by Location/Product

    Results for the Six Months Ended of the FYE March 2026 Consolidated Net Sales by Location /Product FYE Mar.2026 FYE Mar.2025 YoY change interim period interim period （Unit : Millions of yen , ％） Ratio to Amount of Ratio of Ratio to Results sales change Results sales change Japan 6,362 54.8 +20 +0.3

  9. Slide 9: Japanese Market

    e Japanese Mar ae ket

  10. Slide 10: Total Sales in Japan

    Japanese Market Total Sales in Japan Sales 6,362M yen Review YoY Change （vs24/9＋0.3%） （Unit : Millions of yen）  Interim Period Sales High 7,000 Recorded Although sales in Trauma and Spine 6,000 segments declined, growth in the Joint 5,000 segment resulted in domestic Japanese sales increasing by ¥2

  11. Slide 11: Sales in Japan – Joint

    Japanese Market Sales in Japan – Joint Sales 2,421M yen Review *1 THA：Total Hip Arthroplasty YoY Change （vs24/9＋2.0%） 【Hip Joints】 *2 BHA：Bipolar Hip Arthroplasty （Unit : Millions of yen）  THA achieved double-digit growth, partly due to the acquisition of new facilities. *1 3,000 Third-party Produc

  12. Slide 12: Sales in Japan – Trauma

    Japanese Market Sales in Japan – Trauma Sales 2,088M yen Review YoY Change （vs24/9△2.1%）  Main Products （Unit : Millions of yen） Femoral neck fracture products 3,000 ODEV Products PHS , ASULOCK Third-party Products Due to intensifying competition, single-digit growth 2,500 compared to the same peri

  13. Slide 13: Sales in Japan – Spine

    Japanese Market Sales in Japan – Spine Sales 1,743M yen Review YoY Change （vs24/9△0.3％）  BKP：KMC Balloon Kyphoplasty （Unit : Millions of yen） Double-digit growth continues amid market 2,000 ODEV Products Third-party Products expansion  The number of acquired cases for procedures such as pedicle sc

  14. Slide 14: U.S Market

    U.S Market 14

  15. Slide 15: Total Sales in U.S.

    U.S Market Total Sales in U.S. Sales ＄35.8M Review YoY Change （vs24/9△0.4%） （Unit ： Million of dollars） 40 5,200 M yen (△228 M yen) 35  U.S. sales declined due to reduced 30 sales of products affected by 25 temporary supply constraints 20 【Conversion rate :146.58yen/US＄】 15 （24/9：152.34yen/US$） 10

  16. Slide 16: Sales in U.S. – Knee joints

    U.S Market Sales in U.S. – Knee joints Sales ＄24.1M 振り返り YoY Change （vs24/9△1.7%）  BKS TriMax ： Double-digit growth （Unit ： Million of dollars） BKS Revision Knee ： Double-digit revenue 30 decline Delays in delivery of certain components 25 outsourced to external manufacturers Main products 20 Doubl

  17. Slide 17: Sales in U.S. – Hip joints

    U.S Market Sales in U.S. – Hip joints Sales ＄11.5M 振り返り YoY Change （vs24/9+1.9%）  New “Trivicta Hip Stem” Accelerated Growth （Unit ： Million of dollars）  Entrada Hip Stem ： Decrease in the number of acquired cases 15 New “Trivicta Hip Stem” Market Trend: Introduction of Triple Taper Type Stem • Sc

  18. Slide 18: Review of the Six Months Ended for the FYE March 2026

    Review of the Six Months Ended for the Fiscal Year Ending March 2026 ２ 18

  19. Slide 19: Key Initiatives and Results of the Six Months Ended of the FYE March 2026

    Review of the Six Months Ended Key Initiatives and Results of the Six Months Ended for the FYE March 2026 of the FYE March 2026 Area Details of Initiatives  Product Portfolio Review Development  Accelerate new product development to expand product lineup SAICO Project Status  Reduction of manufac

  20. Slide 20: SAICO Project Progress Report

    SAICO Project Progress Report Strategic Actionable Initiatives for Cost Optimization A project launched by our group with the aim of reducing costs by What is the SAICO Project? strengthening our in-house manufacturing capabilities and procurement capabilities １．Reduction of manufacturing costs by ２

  21. Slide 21: SAICO Project Progress Report

    SAICO Project Progress Report ２-2．Cost reduction and risk mitigation ２-3．Cost reduction and risk mitigation through enhanced procurement capabilities through enhanced procurement capabilities Reduction in manufacturing costs through Procurement of Chinese-made medical procurement from regions less a

  22. Slide 22: Japan New Product Information: Ovation Tribute NEO Stem

    【Japan New Product Information】 Hip joint Ovation Tribute NEO Stem In the Japanese market, a new product with a new concept has been added to our hip joint product group, and we are expecting to expand domestic sales. Hip joint stem “Ovation Tribute NEO Stem” March 2025 （Sales begin in Mar. 2025） Ov

  23. Slide 23: U.S. New Product Information: Trivicta Hip Stem

    【U.S. New Product Information】 Hip joint Trivicta Hip Stem We have commenced nationwide sales of the new “Trivicta Hip Stem” product, featuring a triple-taper shape that meets growing demand in the U.S. market, aiming to acquire new customers. Scheduled to begin nationwide sales in the U.S. トリプル・ st

  24. Slide 24: Factors Contributing to the Deterioration of the Cost of Sales Ratio

    Review of the Six Months Ended Factors Contributing to the Deterioration of the for the FYE March 2026 Cost of Sales Ratio ➡Cost of Sales Ratio: 39.5% (+3 Pt YoY) Revenue decline due to supplier supply issues SAICO Project ・Expanding In-House ➡Sales decreased due to supply constraints of Manufacturi

  25. Slide 25: Strengthening Compliance Management

    Review of the Six Months Ended for the FYE March 2026 Strengthening Compliance Management Measures to Prevent Recurrence of the Damages Claim Lawsuit Occurring at the U.S. Subsidiary  Efforts to Prevent Recurrence Project Project Phase １ Phase 1. July 2025 : Utilization of External Consultants 2. I

  26. Slide 26: Full-Year Earnings Forecast for March 2026

    Full-Year Earnings Forecast for March 2026 ３ 26

  27. Slide 27: Prerequisites

    Full-Year Earnings Forecast for March 2026 Prerequisites Assumptions underlying the full-year earnings forecast for the FYE March 2026 Exchange Rate Exchange Rate Reimbursement Price Manufacturing cost （US＄） Fluctuation Impact Reductions 0 Operating profit Impact of Additional Assumed exchange for t

  28. Slide 28: Consolidated Income Statement (After correction)

    Full-Year Earnings Forecast for March 2026 (After correction) Consolidated Income Statement FYE Mar.2026 Compared to FYE Mar.2025 (full year) previous period (full year) （Unit : Millions of yen , ％） Ratio to Amount of Ratio of Ratio to Forecast Results sales change change sales Net sales 24,800 100.

  29. Slide 29: Consolidated Income Statement (Comparison with initial forecast)

    Full-Year Earnings Forecast for March 2026 (Comparison with initial forecast) Consolidated Income Statement FYE Mar.2026 FYE Mar.2026 Increase/decrease (Full year) Initial forecast （Unit : Millions of yen , ％） Ratio to Amount of Ratio of Ratio to Forecast Forecast sales change change sales Net sales

  30. Slide 30: Consolidated Net Sales by Location/Product (After correction)

    Full-Year Earnings Forecast for March 2026 (After correction) Consolidated Net Sales by Location/Product FYE Mar.2026 Compared to previous FYE Mar.2025 (full year) period (full year) （Unit : Millions of yen , ％） Ratio to Amount of Ratio of Ratio to Forecast Results sales change change sales Japan 13

  31. Slide 31: Consolidated Net Sales by Location/Product (Comparison with initial forecast)

    Full-Year Earnings Forecast for March 2026 (Comparison with initial forecast) Consolidated Net Sales by Location/Product FYE Mar.2026 FYE Mar.2026 Increase/decrease (full year) Initial forecast （Unit : Millions of yen , ％） Ratio to Amount of Ratio of Ratio to Forecast Forecast sales change change sa

  32. Slide 32: Key Initiatives for the 2H of the FYE March 2026

    Full-Year Earnings Forecast for March 2026 Key Initiatives for the 2H of the FYE March 2026 Area Details of Initiatives • Expanding Sales Through Strengthening Expertise and Sales Structure via Business Division System • Accelerate new product development to expand product lineup Sales • Expanding S

  33. Slide 33: Contributing to Medical Care Through the Development and Sale of Advanced Medical Devices

    Contributing to Medical Care Through the Development and Sale of Advanced Medical Devices. Japan Medical Dynamic Marketing,INC. E-MAIL WEB SITE Investor Relations Office ir@jmdm.co.jp https://www.jmdm.co.jp/en/ Regarding forward-looking statements  Statements regarding the future, such as business

Japan Medical Dynamic Marketing — H1 FY2026 Earnings Presentation on 6ix